RCKT

1.9656.87%
GD

Gaurav D. Shah

CEO & Director

Dr. Gaurav D. Shah, MD, was Advisor of Genenta Science S.p.A. from July 2024 until 2025. Dr. Shah has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Executive Officer and Director of Rocket Pharmaceuticals, Ltd since January 2018 and served as its President. He serves as the Director at Altheia Science S.r.l. He served as Director at Tourmaline Bio, Inc. Prior to joining Private Rocket, from 2011 to 2015, Dr. Shah held various leadership positions at Novartis including Global Program Head for CART-19, Global Clinical Program Head for CTL-019 and Biosimilars and Global Clinical Leader for Afinitor. He also serves on the board of Altheia Science. Prior to joining industry, Dr. Shah was Assistant Professor of Medicine/Oncology at Columbia University. Dr. Shah started career in industry at ImClone/Eli Lilly as a Medical Director overseeing oncology trials focused on monoclonal antibodies. Dr. Shah holds his BSc in behavioral neuroscience from Harvard College (summa cum laude, Phi Beta Kappa) and a MD from Columbia University. Dr. Shah also completed his internal medicine residency at Brigham and Women’s Hospital and hematology/oncology fellowship training at Memorial-Sloan Kettering.

Positions